Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | ELANE | P08246 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6321209 | 0.83 | GAA (0.52) | GAALMNAHSD17B10ALDH1A1 | |
| SCHEMBL6314947 | 0.81 | GAA (0.56) | GAALMNAHSD17B10ELANEALDH1A1 | |
| SCHEMBL6314370 | 0.79 | GAA (0.54) | GAALMNAHSD17B10ELANEALDH1A1 | |
| SCHEMBL1579162 | 0.73 | GAA (0.50) | GAALMNAHSD17B10ELANEALDH1A1 | |
| SCHEMBL12776904 | 0.73 | GAA (0.50) | GAALMNAHSD17B10ELANEALDH1A1 | |
| SCHEMBL11223353 | 0.71 | GAA (0.43) | GAALMNAHSD17B10ALDH1A1 | |
| SCHEMBL21542084 | 0.71 | GAA (0.43) | GAALMNAHSD17B10ALDH1A1 | |
| SCHEMBL12776902 | 0.70 | GAA (0.46) | GAALMNAHSD17B10ALDH1A1 | |
| SCHEMBL28349840 | 0.70 | GAA (0.46) | GAALMNAHSD17B10ALDH1A1 | |
| SCHEMBL21542085 | 0.70 | GAA (0.46) | GAALMNAHSD17B10ELANEALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6927291-B2 | Method for the synthesis of 2′,3′-dideoxy-2′,3′-didehydronucleosides | PHARMASSET, LTD. (US) | 2005-08-09 | — | — | US | claimed |
| EP-1363927-A2 | METHOD FOR THE SYNTHESIS OF 2',3'-DIDEOXY-2',3'-DIDEHYDRONUCLEOSIDES | Pharmasset Limited (US) | 2003-11-26 | — | — | EP | claimed |
| US-20020198224-A1 | Method for the synthesis of 2',3'-dideoxy-2',3'-didehydronucleosides | GILEAD PHARMASSET LLC | 2002-12-26 | — | — | US | claimed |
| WO-2002070533-A2 | METHOD FOR THE SYNTHESIS OF 2',3'-DIDEOXY-2',3'-DIDEHYDRONUCLEOSIDES | PHARMASSET LTD. (BB) | 2002-09-12 | — | — | WO | claimed |
| US-20050250946-A1 | Method for the synthesis of 2',3'-dideoxy-2',3'-didehydronucleosides | PHARMASSET, INC. | 2005-11-10 | — | — | US | disclosed |
| US-6927291-B2 | Method for the synthesis of 2′,3′-dideoxy-2′,3′-didehydronucleosides | PHARMASSET, LTD. (US) | 2005-08-09 | — | — | US | disclosed |
| EP-1363927-A2 | METHOD FOR THE SYNTHESIS OF 2',3'-DIDEOXY-2',3'-DIDEHYDRONUCLEOSIDES | Pharmasset Limited (US) | 2003-11-26 | — | — | EP | disclosed |
| US-20020198224-A1 | Method for the synthesis of 2',3'-dideoxy-2',3'-didehydronucleosides | GILEAD PHARMASSET LLC | 2002-12-26 | — | — | US | disclosed |
| WO-2002070533-A2 | METHOD FOR THE SYNTHESIS OF 2',3'-DIDEOXY-2',3'-DIDEHYDRONUCLEOSIDES | PHARMASSET LTD. (BB) | 2002-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198224-A1 | Method for the synthesis of 2',3'-dideoxy-2',3'-didehydronucleosides | DUT, DUS2, DERA | GAA 627/4885LMNA 696/4885HSD17B10 550/4885 |
| US-20050250946-A1 | Method for the synthesis of 2',3'-dideoxy-2',3'-didehydronucleosides | DUT, DERA, DUS2 | GAA 491/4885LMNA 477/4885HSD17B10 493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.